Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 288
- Registration Number
- NCT01318109
Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 312
- Registration Number
- NCT01318083
Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 339
- Registration Number
- NCT01318070
A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT01317797
- Locations
- 🇳🇱
Nycomed Investigational Site, Leids, Netherlands
TAK-329 Glucose Clamp Study
Phase 1
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 37
- Registration Number
- NCT01311076
Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease
Phase 3
Completed
- Conditions
- Safety
- Interventions
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 153
- Registration Number
- NCT01309828
Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 17
- Registration Number
- NCT01299805
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
Phase 2
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2011-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 926
- Registration Number
- NCT01289132
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 506
- Registration Number
- NCT01289119
Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 438
- Registration Number
- NCT01263496
© Copyright 2025. All Rights Reserved by MedPath